Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Stereotactic Body Radiation Therapy Sbrt

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

50%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Phase 1/2 (1)
Phase 3 (1)

Trial Status

Completed1
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT00591838Phase 1/2CompletedPrimary

A Phase I/II Trial of Stereotactic Body Radiation Therapy

NCT01579188Phase 3UnknownPrimary

Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer

Showing all 2 trials

Research Network

Common Treatments

  • Stereotactic Body Radiation Therapy Sbrt1
  • Gv10011
  • Normal Saline1

Active Sponsors

  • Quintiles, Inc.1
  • Washington University School of Medicine1
  • Kael-GemVax Co., Ltd.1

Top Investigators

Activity Timeline